| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
DNA synthesis; RNA metabolism; viral reverse transcriptase. 5-Bromouridine is a purine nucleoside analog that inhibits DNA synthesis and induces apoptosis. It is incorporated into RNA and can be detected by antibodies. It possesses anti-viral activity and inhibits HIV. The compound is photoreactive and can cross-link RNA upon UV irradiation.
|
|---|---|
| ln Vitro |
5-Bromouridine demonstrates activity as a purine nucleoside analog in cellular assays. It induces apoptosis and halts the cell cycle at the S phase in HL-60 cells with an LC50 of 10 μM. It shows activity against MOLT-4 cells with an LC50 of 20 μM. It has broad antitumor activity and antiviral activity against HIV.
|
| ln Vivo |
5-Bromouridine possesses anti-viral activity and inhibits viruses such as human immunodeficiency virus. It induces apoptosis in cancer cells by inhibiting DNA synthesis. The compound is used as a marker for DNA and RNA, where the molecule is labeled with a radioisotope or pigment after being introduced into a DNA or RNA strand.
|
| Enzyme Assay |
In vitro assays for 5-Bromouridine involve measuring inhibition of DNA synthesis using radiolabeled thymidine incorporation. For RNA incorporation studies, cells are treated with the compound and RNA is extracted for detection using anti-bromodeoxyuridine antibodies. Cell viability is assessed by MTT assays. Apoptosis is evaluated by caspase activation or flow cytometry.
|
| Cell Assay |
Cells (e.g., HL-60, MOLT-4, or other cancer cell lines) are cultured and treated with 5-Bromouridine at concentrations typically ranging from 1–100 μM for 24–72 hours. DNA/RNA synthesis inhibition is measured by BrdU incorporation or nucleotide analog detection. Cell cycle analysis is performed by flow cytometry. Apoptosis is evaluated by standard assays. For photo-crosslinking, cells are exposed to UV light after treatment.
|
| Animal Protocol |
In vivo animal studies for 5-Bromouridine have not been extensively reported. The compound is primarily used as an in vitro research tool for RNA labeling and tracking. Its antiviral activity suggests potential for in vivo studies in viral infection models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5-Bromouridine have not been published. The compound has a molecular weight of 323.10 and formula C9H11BrN2O6. As a nucleoside analog, it is expected to be taken up by cells via nucleoside transporters. In vivo PK parameters have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for 5-Bromouridine have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling brominated compounds should be observed.
|
| References | |
| Additional Infomation |
5-Bromouridine is a uridine with a bromine substituent at the 5-position. It acts as a mutagen.
5-Bromouridine (CAS: 957-75-5, molecular formula C9H11BrN2O6, molecular weight 323.10) is a brominated uridine analog. It is incorporated into RNA and detected by antibodies. It induces apoptosis in HL-60 cells (LC50 = 10 μM). It has antiviral activity against HIV. It is photoreactive and used for RNA cross-linking. It is not in clinical trials. |
| Molecular Formula |
C9H11BRN2O6
|
|---|---|
| Molecular Weight |
323.10
|
| Exact Mass |
321.98
|
| CAS # |
957-75-5
|
| PubChem CID |
91494
|
| Appearance |
White to off-white solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Melting Point |
180-182 °C (dec.)(lit.)
|
| Index of Refraction |
1.691
|
| LogP |
-0.92
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
414
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)Br
|
| InChi Key |
AGFIRQJZCNVMCW-UAKXSSHOSA-N
|
| InChi Code |
InChI=1S/C9H11BrN2O6/c10-3-1-12(9(17)11-7(3)16)8-6(15)5(14)4(2-13)18-8/h1,4-6,8,13-15H,2H2,(H,11,16,17)/t4-,5-,6-,8-/m1/s1
|
| Chemical Name |
5-bromo-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0950 mL | 15.4751 mL | 30.9502 mL | |
| 5 mM | 0.6190 mL | 3.0950 mL | 6.1900 mL | |
| 10 mM | 0.3095 mL | 1.5475 mL | 3.0950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
